The estimated Net Worth of Steve Miller is at least $21.6 Milion dollars as of 20 August 2024. Steven Miller owns over 150,000 units of Catalyst Pharmaceuticals Inc stock worth over $13,137,913 and over the last 17 years he sold CPRX stock worth over $7,015,168. In addition, he makes $1,416,390 as Chief Operating Officer i Chief Scientific Officer at Catalyst Pharmaceuticals Inc.
Sign up
Steven Miller CPRX stock SEC Form 4 insiders trading
Steven has made over 22 trades of the Catalyst Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 150,000 units of CPRX stock worth $3,052,500 on 20 August 2024.
The largest trade he's ever made was exercising 200,000 units of Catalyst Pharmaceuticals Inc stock on 6 November 2017 worth over $94,000. On average, Steven trades about 40,857 units every 108 days since 2008. As of 20 August 2024 he still owns at least 675,124 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Steven Miller stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Miller biography
Dr. Steven R. Miller, Ph.D. is Chief Operating Officer, Chief Scientific Officer of Catalyst Pharmaceutical Partners Inc. Previously, commencing in April 2007, Dr. Miller was our Vice President of Pharmaceutical Development and Project Management. Dr. Miller has worked in the healthcare industry for over 30 years. Prior to joining us, Dr. Miller spent 15 years with various divisions of Watson Laboratories, a subsidiary of Watson Pharmaceuticals, Inc., most recently as Executive Director of R&D Operations. In this capacity, Dr. Miller managed a team of 75 in the testing of all R&D products for clinical trials, including method valuation, stability testing, operation of the R&D pilot plant, and assembly of the CMC section of drug applications, in addition to other responsibilities. Prior to holding this position, Dr. Miller was Director of Technology Transfer for Watson Laboratories, and Vice President of Research and Product Development for Royce Laboratories, which was subsequently acquired by Watson Laboratories. Prior to joining Royce Laboratories, Dr. Miller was Group Leader and Senior Scientist at Dade Behring. Prior to that, he served as an Analytical Chemist at the U.S. Food & Drug Administration. Dr. Miller received his Bachelor of Science Degree in Chemistry from the University of Maryland and his Ph.D. from the University of Miami.
What is the salary of Steven Miller?
As the Chief Operating Officer i Chief Scientific Officer of Catalyst Pharmaceuticals Inc, the total compensation of Steven Miller at Catalyst Pharmaceuticals Inc is $1,416,390. There are 1 executives at Catalyst Pharmaceuticals Inc getting paid more, with Patrick McEnany having the highest compensation of $3,371,560.
How old is Steven Miller?
Steven Miller is 58, he's been the Chief Operating Officer i Chief Scientific Officer of Catalyst Pharmaceuticals Inc since 2011. There are 9 older and 7 younger executives at Catalyst Pharmaceuticals Inc. The oldest executive at Catalyst Pharmaceuticals Inc is Charles O'Keeffe, 80, who is the Lead Independent Director.
What's Steven Miller's mailing address?
Steve's mailing address filed with the SEC is 355 Alhambra Cir #1250, Coral Gables, FL 33134, USA.
Insiders trading at Catalyst Pharmaceuticals Inc
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over $35,595,986 worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth $7,307,159 . The most active insiders traders include Pharmaceutical Inc Biomarin, Patrick J Mcenany oraz Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $1,097,019. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth $60,150.
What does Catalyst Pharmaceuticals Inc do?
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
What does Catalyst Pharmaceuticals Inc's logo look like?
Complete history of Steven Miller stock trades at Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc executives and stock owners
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Patrick McEnany,
Chairman of the Board, President, Chief Executive Officer -
Steven Miller,
Chief Operating Officer, Chief Scientific Officer -
Gary Ingenito,
Chief Medical Officer and Head of Regulatory Affairs -
Patrick J. McEnany,
Co-Founder, Chairman, Pres & CEO -
Dr. Steven R. Miller,
COO & Chief Scientific Officer -
Dr. Gary Ingenito,
Chief Medical & Regulatory Officer -
Alicia Grande,
Chief Accounting Officer, VP, Treasurer & CFO -
Alicia Grande,
Chief Financial Officer, Vice President, Treasurer -
Jeffrey Del Carmen,
Chief Commercial Officer -
Brian Elsbernd,
Chief Compliance Officer, Chief Legal Officer -
Charles O'Keeffe,
Lead Independent Director -
Donald Denkhaus,
Independent Director -
David Tierney,
Independent Director -
Richard Daly,
Independent Director -
Jeffrey Del Carmen,
Chief Commercial Officer -
Philip B. Schwartz,
Corp. Sec. -
Dr. Preethi Sundaram Ph.D.,
Chief Product Devel. Officer -
Pete Curry Sr.,
VP of Sales -
Brian Elsbernd J.D.,
Chief Compliance Officer & Chief Legal Officer -
Mary Coleman,
VP & Head of Investor Relations -
Philip H Coelho,
Director -
Paul J Merrigan,
Chief Commercial Officer -
M Douglas Winship,
V.P. of Regulatory Operations -
Daniel Brennan,
Chief Commercial Officer -
Tamar Thompson,
Director -
David D Muth,
Exec. V.P., Corp. Development -
Hubert E Md Huckel,
Director -
Milton J Wallace,
Director -
Pharmaceutical Inc Biomarin,
10% owner -
Jack Weinstein,
V.P., Treasurer & CFO -
Molly Harper,
Director -
Preethi Sundaram,
Chief Strategy Officer -
Steve Miller,
Chief Op. & Scientific Officer